Vericel Corp VCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $37.46
- Day Range
- $37.21–38.59
- 52-Week Range
- $28.95–43.57
- Bid/Ask
- $30.50 / $40.15
- Shares Outstanding
- 51.07M
- Market Cap
- $1.96B
- Volume/Avg
- 33 / 659,860
Key Statistics
- Price/Earnings (Normalized)
- 89.19
- Price/Sales
- 6.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 398
- Website
- https://www.vcel.com
Valuation
|
Metric
|
VCEL
|
|---|---|
Price/Earnings (Normalized) | 89.19 |
Price/Book Value | 5.36 |
Price/Sales | 6.72 |
Price/Cash Flow | 24.88 |
Price/Earnings
VCEL
Financial Strength
|
Metric
|
VCEL
|
|---|---|
Quick Ratio | 4.62 |
Current Ratio | 5.18 |
Interest Coverage | 24.74 |
Quick Ratio
VCEL
Profitability
|
Metric
|
VCEL
|
|---|---|
Return on Assets (Normalized) | 11.35% |
Return on Equity (Normalized) | 15.88% |
Return on Invested Capital (Normalized) | 11.01% |
Return on Assets
VCEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vdsyjsmq | Byvvdw | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gnkyqypl | Qdjbpyl | $64B | |||
| argenx SE ADR
ARGX
| Qwhncxm | Qnxsj | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qcnjhwnc | Smbrjd | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Vdtsvfsvm | Qwkqg | $24B | |||
| BioNTech SE ADR
BNTX
| Byrnlxdk | Kdptm | $23B | |||
| Incyte Corp
INCY
| Nsqsfbn | Cszh | $22B | |||
| Moderna Inc
MRNA
| Yslynwhbn | Lmyg | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qqkrfvdh | Vtrkh | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Sznxggml | Wlg | $13B |
United States